Analysis of the impact of pancreatic tumors with abnormal blood glucose on tumor markers
Objective To explore the impact of pancreatic tumors with abnormal blood glucose on tumor markers.Methods 80 patients cases of pancreatic tumor were selected,including 40 patients with benign pancreatic tumors(20 patients with normal blood glucose and 20 patients with abnormal blood glucose)and 40 patients with malignant pancreatic tumors(20 patients with normal blood glucose and 20 patients with abnormal blood glucose).Tumor markers were examined in both groups.The levels of carbohydrate antigen 199(CA199),carcinoembryonic antigen(CEA),alpha-fetoprotein(AFP),glycochain antigen 125(CA125)and carbohydrate antigen 153(CA153)in patients with benign pancreatic cancer and malignant pancreatic cancer were compared,as well as in benign pancreatic tumor patients with normal and abnormal blood glucose,and malignant pancreatic tumor patients with normal and abnormal blood glucose.Results In patients with malignant pancreatic tumors,CA199 was(76.37±10.16)U/ml,CEA was(26.13±6.38)ng/ml,AFP was(22.32±7.19)ng/ml,CA125 was(63.85±12.11)U/ml,and CA153 was(45.96±10.27)U/ml,which were significantly higher than(13.20±2.11)U/ml,(2.65±0.35)ng/ml,(3.37±0.13)ng/ml,(13.79±2.02)U/ml,and(7.92±1.21)U/ml in patients with benign pancreatic tumors(P<0.05).In malignant pancreatic tumor patients with abnormal blood glucose,CA199 was(86.41±10.19)U/ml,CEA was(30.63±6.26)ng/ml,AFP was(28.13±8.27)ng/ml,CA125 was(68.77±3.10)U/ml,and CA153 was(50.16±4.24)U/ml,which were higher than(66.33±10.14)U/ml,(21.63±7.22)ng/ml,(16.51±7.24)ng/ml,(58.93±3.02)U/ml,and(41.76±4.21)U/ml of those with normal blood glucose(P<0.05).Conclusion For patients with pancreatic cancer,abnormal blood glucose has a significant impact on tumor marker indicators,which should be paid attention to and properly controlled,so as to lay a good condition for further treatment of the disease.
NETL
NSTL
万方数据
